newsfilter
← Latest News
Business Wire·

Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection

Cortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpr